Beta Bionics, Inc. (NASDAQ:BBNX) Given Average Rating of “Hold” by Analysts

Beta Bionics, Inc. (NASDAQ:BBNX) has received an average recommendation of “Hold” from the three research firms that are currently covering the company, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating. The average 12-month target price among brokers that have covered the stock in the last year is $20.00.

BBNX has been the subject of a number of recent analyst reports. Leerink Partners initiated coverage on shares of Beta Bionics in a research report on Monday. They set an “outperform” rating and a $28.00 price target for the company. Baird R W raised shares of Beta Bionics to a “hold” rating in a research report on Thursday. Stifel Nicolaus initiated coverage on Beta Bionics in a report on Monday. They issued a “buy” rating and a $25.00 price objective for the company. LADENBURG THALM/SH SH assumed coverage on Beta Bionics in a report on Thursday. They set a “neutral” rating and a $20.00 target price on the stock. Finally, Piper Sandler assumed coverage on Beta Bionics in a report on Monday. They issued an “overweight” rating and a $26.00 price target for the company.

Beta Bionics Price Performance

Shares of BBNX opened at $20.57 on Monday. Beta Bionics has a one year low of $20.57 and a one year high of $24.50.

Insider Transactions at Beta Bionics

In other news, insider Mike Mensinger acquired 33,350 shares of the business’s stock in a transaction dated Friday, January 31st. The stock was acquired at an average price of $17.00 per share, for a total transaction of $566,950.00. Following the completion of the acquisition, the insider now directly owns 59,019 shares in the company, valued at $1,003,323. This represents a 129.92 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Hadley Harbor Aggre Wellington bought 1,000,000 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were purchased at an average cost of $17.00 per share, with a total value of $17,000,000.00. Following the purchase, the insider now directly owns 3,901,599 shares of the company’s stock, valued at approximately $66,327,183. This represents a 34.46 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

About Beta Bionics

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.